---
title: "TLDR_kim_1529p_2019"
date: "2024-06-16"
enableToc: false
tags:
    - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ªï¼š[[TLDR_brignole2018ESCGuidelines2018]]

# TLDR_kim_1529p_2019



1. Ahn MJ, Yang JCH, Yu HA, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. Journal of Thoracic Oncology. 2016;11(4):S115-NA. doi:10.1016/s1556-0864(16)30246-5
2. 
1
1. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal. 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037
2. 
> [!NOTE]
> [[LitNote/kelleyCabozantinibAtezolizumabSorafenib2022.md|Kelley. 2022. *Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial*]]
> [Open in Zotero](zotero://select/items/1_LJVZ7YC2)
> CiteKeyðŸ”‘: [@kelleyCabozantinibAtezolizumabSorafenib2022]
